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Abstract   
Findings from observational studies and clinical trials on the associations between 
vitamin E and dementia remain controversial. Here we conducted a meta-analysis to 
determine the difference in blood tocopherols levels between patients with Alzheimer’s 
disease (AD) or age-related poor cognitive function and healthy controls. 
Standardised mean difference (SMD) and 95% confidence intervals (CIs) were 
calculated and entered into a random effects model. Study quality, heterogeneity and 
publication bias were also investigated. 
Thirty-one articles were included in the meta-analysis, which included analyses for α-
, β-, γ- and δ-tocopherols. These results indicated that individuals with AD or age-
related cognitive deficits and mild cognitive impairment (MCI) had lower circulatory 
concentrations of α-tocophenol compared with healthy controls (AD: SMD = −0.97, 
95% confidence interval [CI] = −1.27 to −0.68, Z = 6.45, P < 0.00001; age-related 
cognitive deficits and MCI: SMD = −0.72, 95% CI = −1.12 to −0.32, Z = −3., P < 
0.0005). Levels of β-, γ- and δ-tocophenols did not significantly differ between groups 
of AD and age-related cognitive deficits compared to controls.  
These results suggest that lower α-tocopherol levels have a strong association with 
AD and MCI supporting evidence for the role of diet and vitamin E in AD risk and age-
related cognitive decline.  
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Introduction 
Several studies have proposed different factors that may contribute to the risk of 
developing Alzheimer’s disease (AD), including genetic and environmental factors  
such as exposure to pesticides, paints and glues, as well as lifestyle factors such as 
lack of exercise, smoking and alcohol consumption, and a diet lacking vegetables and 
fruit [1]. 
Dietary intake has been progressively examined as a potential independent risk factor 
of the age-related cognitive decline and dementia, and the intake of certain nutrients 
such as vitamin E have been implicated in healthy brain function, though results are 
conflicting [2,3]. Vitamin E is an essential dietary micronutrient  comprising a group of 
structurally-related forms including four different tocopherols. α–tocopherol is the most 
bioavailable antioxidant isoform of vitamin E in the human body and most often used 
in supplements. Vitamin E is found in vegetable oils and products derived from 
vegetables whole grains, nuts and seeds, animal fats and meats, with variations in 
levels of tocopherols between food sources for examples while some oils, such as 
soybean oil, contain a mix of tocopherols, others, such as sunflower oil, contain almost 
exclusively α-tocopherol (for further review see [4]). 
Tocopherols have antioxidant and anti-inflammatory properties. Interestingly, there 
are variations in antioxidant activity between tocopherols with some forms more 
effective than others at neutralizing some free radicals. Each form also has unique 
biological functions, linked to variations in immune activity, hypocholesterolemic 
properties and modulation of different signalling pathways (for review see [5]). 
Considering the large numbers of studies showing the crucial role of oxidative stress 
in the development of neurodegenerative disorders (for review see [6]), levels of 
antioxidants and their supplements have been proposed as preventive measures 
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against dementia. Though, experimental studies indicate that vitamin E exerts 
beneficial effects in animal models (for review see [7]), its efficacy in AD patients is 
controversial. For example, one of the earliest double-blind, randomized multicenter 
clinical trials [8] showed vitamin E slowed AD progression, though several subsequent 
double-blind study studies such as [9] found vitamin E supplementation had no benefit 
(for review see [10]). Two recent Cochrane reviews [11,12] were also unable to 
support evidence for the role of vitamin E supplementation, concluding that the amount 
and quality of research evidence was limited.  
Results from studies investigating serum levels of tocopherols in dementia and mild 
cognitive impairment (MCI) have again, been contentious. For example Iuliano and 
colleagues [13] found no significant difference in serum α–tocopherol between 
patients with AD and age-matched controls while Mangialasche and colleagues [14] 
suggested that low levels were associated with increased risk of AD. Other studies 
have also led to conflicting conclusions regarding MCI and age-related cognitive 
decline [15]. Two meta-analyses on α–tocopherol and AD  [16,17] did not find  
significant differences, however they both focussed only on AD and not MCI, and only 
on α-tocopherol. They also did not account for variations in measurement of 
tocopherols, particularly whether some studies controlled for cholesterol and were 
relatively restricted in the numbers of studies included in the analyses. Importantly, 
there are also numerous other associated risk factors, such as increasing age, female 
gender, and APOE4 genotype, as well as other variables implicated in some studies, 
such as family history of Alzheimer disease, depression, low educational level, 
smoking, diabetes, obesity, hypertension, and fatty diet (for review see [18]). 
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Thus, the aim of this study was to conduct a meta-analysis examining current literature 
regarding levels of different tocopherols in case-control studies for AD and MCI 
accounting for differences in variations in how levels of tocopherols were measured 




This meta-analysis was performed in accordance to the Preferred Reporting Items for 
Systematic Review and Meta-analysis (PRISMA) statement [19] to answer the 
following question: do blood levels of α-, γ-,  β- or δ-tocopherol differ between 
individuals with AD or MCI, compared with age-matched controls? 
Search strategy 
We searched the Scopus, PubMed, Science Direct and Google Scholar databases up 
to 9th April 2019. When available, search terms were limited to those reported in the 
English language and to journal articles which consisted of ("tocopherol" OR "Vitamin 
E") AND (“dementia” OR "cognitive" OR “Alzheimer’s”). In addition, we evaluated the 
reference lists of the identified articles to identify relevant studies. 
Inclusion and exclusion criteria 
All the studies included in this meta-analysis abided by the following criteria. (1) Study 
design: case-control or cross-sectional. (2) Measure: α-, β-, γ- or δ-tocopherol blood 
levels. (3) Subjects: comprehensive assessment tools for dementia, AD and MCI. (4) 
Statistical analysis: studies contained mean serum or plasma levels of tocopherols 
together with standard deviations (SDs) or had other data that could be converted to 
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mean SD (See the Data Extraction section below). (5) Methodological: studies 
measuring serum levels use high performance liquid chromatography (HPLC) in either 
serum or plasma. 
Data extraction 
Data and characteristics extracted from each study included: study design, location, 
number of subjects, age, percentage of females, assessment of dementia, 
assessment of tocopherol levels and their levels. As lipophylic α-tocopherol is carried 
in lipoprotein, its concentration is highly dependent on the level of plasma lipid. Thus, 
it has been proposed that vitamin E evaluation in plasma requires lipid standardization, 
specially total cholesterol (TC) [20]. We therefore took measures controlled for TC if 
available. To convert mean and 95% CI data in Sinclair et al. 1998 study [21] to SD 
the length of the confidence interval was divided by 3.92 and multiplied by the square 
root of the sample size. Median and interquartile range (IQR) data from the Foy et al. 
1999 study  [22] was converted to mean and SD using the formula described [23,24] 
and SE data from the Feillet-Coudray et al. 1999 [25,26] and Battino et al. 1997 studies 
[25,26] were converted to SD by dividing by the square root of the samples size. 
Quality assessment 
We developed a scale to assess the quality of selected studies for validation of the 
cases and healthy controls and, whether the individuals were excluded if they had 
other diseases, alcohol addiction, smoked, took recreational drugs and vitamin 
supplements. Studies were also assessed if they controlled for BMI, abnormal diets or 
malnutrition, and if there were variations in age between the groups or did not contain 
equal genders. Finally, studies were checked whether serum was collected in the 
morning following fasting. Using these criteria, the included studies within this meta-
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analysis were graded for their quality and bias to identifying any reasons for possible 
heterogeneity (Supplementary Table 1). The checklist was followed and the 
publications were graded. 
 
Statistical analysis 
Meta-analyses were performed using the Review Manager 5.3 software by using  
random effect models throughout. Results were reported as standardised mean 
differences (SMD), heterogeneity measured using I2 and publication bias through 
visual inspection of funnel plots. 
 
Results 
Study selection  
The search strategy returned 515 records for which titles and abstracts were screened. 
Out of the 81 full-text journal articles that were assessed for eligibility, 33 were retained 
for methodological quality checks and included in this meta-analysis. These divided 
into 29 studies that examined blood levels of tocopherols in AD and 14 studies that 
tested samples from MCI or age-related cognitive defects – some studies tested both 
groups and multiple tocopherols (Figure 1). 
 
Study characteristics  
Most studies reported male and female participants together, except one study 
reported effects for separate sexes [27]. The majority of studies were case-control, 
while nine were cross-sectional [14,15,27–33]. 
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A number of the studies reported raw serum values tocopherols [25,28,30,34–42] 
either as µmol/l, µg/l while the other studies controlled for TC reporting values as 
µmol/mmol cholesterol. 
 
α-tocopherol and AD and MCI 
Results from the meta-analysis indicate that AD patients have a lower concentration 
of peripheral α-tocopherol compared with healthy age-matched controls (SMD = −0.97 
μmol/L, 95% CI −1.27 to −0.68; Z = 6.45, P < 0.00001) (Figure 2). There was 
heterogeneity amongst the serum level trials (Heterogeneity Tau2 = 0.59; Chi2 = 
425.15, df=29 (p<0.00001); I2 =93%). Subgroup analysis of only studies that controlled 
for cholesterol reduced heterogeneity (Tau2 = 0.18; Chi2 =65.13, df=10 (p<0.00001); 
I2 =85%) while overall effect still remained significant (Z = 2.56, P < 0.01). 
Publication bias was not detected and sensitivity analysis performed by omitting each 
study, and calculating the pooled SMD again for the remaining studies indicated the 
results were stable.  
Serum levels of α-tocopherol were also significantly lower in age-related poor cognitive 
performance and MCI (SMD = −0.72, 95% CI −1.12 to −0.28; Z = 3.51, P < 0.0005) 
(Figure 3). Again, there was heterogeneity amongst the studies (Heterogeneity Tau2 
= 0.54; Chi2 = 457.42, df=13 (p<0.00001); I2 =97%), that was reduced when only 
including studies that controlled for cholesterol (Heterogeneity Tau2 = 0.06; Chi2 = 
28.26, df=7 (p<0.0002); 12 =75%) while significance remained (Z=2.06, P=0.04). 
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γ-tocopherol and AD and MCI 
Results from the meta-analysis indicate no differences in serum concentrations of 
serum γ-tocopherol between AD cases and healthy age-matched controls (SMD = 
−0.14, 95% CI −0.83 to −0.55; Z = 0.41, P =0.69) (Figure 4). There was heterogeneity 
amongst the serum level trials (Heterogeneity Tau2 = 0.48; Chi2 = 99.79, df=3 
(p<0.00001); 12 =97%).  
Serum levels of γ-tocopherol were also not significantly different in MCI and age-
related poor cognitive performance and MCI (SMD = −0.17, 95% CI −0.39 to −0.05; Z 
= 1.47, P = 0.14) (Figure 5). There was heterogeneity amongst the serum level trials 
(Heterogeneity Tau2 = 0.05; Chi2 = 34.04, df=4 (p<0.00001); 12 =88%). 
 
β-tocopherol and AD and MCI 
Results from the meta-analysis indicate no differences in serum concentrations of 
serum γ-tocopherol between AD cases and healthy age-matched controls (SMD = 
−0.05, 95% CI −0.45 to −0.36; Z = 0.22, P =0.82) (Figure 6). There was heterogeneity 
amongst the serum level trials (Heterogeneity Tau2 = 0.11; Chi2 = 13.3, df=2 (p<0.001); 
12 =85%).  
Serum levels of γ-tocopherol were also not significantly different in MCI and age-
related poor cognitive performance and MCI (SMD = −0.19, 95% CI −0.47 to −0.09; Z 
= 1.3, P = 0.19) (Figure 7). There was heterogeneity amongst the serum level trials 
(Heterogeneity Tau2 = 0.04; Chi2 = 6.37, df=2 (p<0.04); 12 =69%). 
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δ-tocopherol and AD and MCI 
Results from the meta-analysis indicate no differences in serum concentrations of 
serum γ-tocopherol between AD cases and healthy age-matched controls (SMD = 
−0.17, 95% CI −0.54 to −0.88; Z = 0.47, P =0.64) (Figure 8). There was heterogeneity 
amongst the serum level trials (Heterogeneity Tau2 = 0.37; Chi2 = 40.58, df=2 
(p<0.00001); 12 =95%).  
Serum levels of γ-tocopherol were also not significantly different in MCI and age-
related poor cognitive performance and MCI (SMD = −0.16, 95% CI −0.45 to −0.14; Z 
= 1.02, P = 0.31) (Figure 9). There was heterogeneity amongst the serum level trials 





This meta-analysis, based on the available data of case-control studies, provides 
evidence that patients with AD and age-related cognitive deficits have lower circulatory 
levels of α-tocophenol. Levels of the other tocopherols did not differ. These findings 
support some of the previous evidence on the potential association of vitamin E with 
AD. 
Regarding possible mechanisms of how vitamin E might relate to AD and MCI, a 
number of studies have demonstrated the beneficial effects of vitamin E 
supplementation on various markers of inflammatory stress, cellular signalling and 
immune function in humans and its influence on AD-associated pathology [43]. It has 
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been shown that vitamin E may be able to counteract oxidative stress induced by 
amyloid-β. For example, Yatin et al. demonstrated that vitamin E prevented amyloid-
β1–42 induced protein oxidation, reactive-oxidative species production, and 
neurotoxicity in primary rat embryonic hippocampal neuronal culture,  possibly through 
the scavenging of amyloid-β-induced free radicals [44]. The enzyme-inhibiting activity 
of various tocopherol isoforms also incorporate several AD-associated enzymes, 
including cyclo-oxygenases, which contribute to neuro-inflammation and oxidative 
stress [45]. The activity of both sub-groups have also been associated with reduced 
amyloid-β production through inhibiting secretase enzyme activity [46]. Similarly, 
vitamin E has been shown to confer a protective effect against hyper-phosphorylated 
tau protein [47]. Studies have also shown that vitamin E deficiency influenced gene 
expression in the hippocampus and in particular, the genes associated with hormones, 
nerve growth factor (NGF), apoptosis, dopaminergic neurotransmission, clearance of 
amyloid-β and advance glycated end products [48]. 
The APOE ε4 allele is associated with an increased risk of AD [18]. Interestingly, of 
those studies within this meta-analysis testing for APOE, there were less significant 
differences (p=0.01) in α-tocophenol levels between AD or MCI and control if APOE 
ε4 allele frequencies did not differ between the groups (Supplementary Figure 2). 
Previous research has shown a significant interaction between APOE genotype on AD 
progression with ε4 carriers declining faster than non-carriers following vitamin E and 
memantine treatment [49]. Possible mechanisms are that APOE may influence AD 
risk though its role in cholesterol transport, one consideration is that vitamin E and 
cholesterol share mechanisms of delivery to cells via LDL particles that genotype 
might influence [18].  
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Other factors may have also influenced these results and influenced vitamin E levels. 
Many of the studies did not account for nutritional status, energy intake and BMI. 
Nutritional status in older adults is an issue of increasing importance and malnutrition 
is associated with functional and cognitive decline in the demented elderly. One study 
has found antioxidants were lower in AD patients compared to the controls, that was 
suggested to be partly due to a different dietary intake of antioxidant nutrients [50]. 
Therefore, in such case-control studies, it is important to consider whether reductions 
in vitamin E may result from dietary changes in AD. This may also relate to BMI, though 
it is important to note that ten of the twenty-five studies found no differences in AD, 
only one reduced BMI. Detailed information on dietary intake might further have 
allowed to control whether reduced Vitamin E levels might have occurred through such 
dietary changes. As such, causal relationships between reduced serum tocopherol 
and AD cannot be determined due to the case-control nature of our study. 
Not all studies controlled for the absence of supplement use, particularly vitamin E, 
among participants that might have been higher in control groups. Cigarette smoking, 
and high alcohol consumption, are important sources of reactive oxygen species 
(ROS), that overwhelm any protective effects associated with α-tocopherol levels. 
Lower levels of vitamin E have also been found in patients with alcoholism [51] and 
drug addiction [52]. These were not exclusion criteria in all studies. 
Several prospective cohort studies have investigated plasma vitamin E levels and the 
subsequent risk of developing AD. While these provide limited evidence for the 
benefits of vitamin E supplementation, they nevertheless suggest that a high intake 
from dietary sources may confer some benefit in reducing the risk of developing AD 
compared to those with lower intake (for review  see [43]). It is further suggested that 
neuroprotective effects may result from a combination of vitamin E isoforms rather 
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than specifically to any individual congener [53]. However, there were only a limited 
number of studies that included β-, γ-, and δ-tocotrienols, in addition to α-, for this 
meta-analysis. In vivo studies have reported higher antioxidant activity of α-tocopherol 
compared to the other isoforms, and it has been suggested that α-tocopherol has a 
greater role in neuroprotection due to its relatively greater bioavailability and 
preferential retention by tissues [54]. However, it has also been suggested that its 
relative laboratory efficacy may be dependent upon experimental conditions 
[55]. Indeed, tocotrienols may exhibit more potent antioxidant activities than 
tocopherols [56].  
Diet is an important source for tocopherols with α-tocopherol the major tocopherol in 
many edible oils as such as almond, peanut, olive, and sunflower oils. The content of 
γ-tocopherol in some edible oils such as canola, corn, camelina, linseed, soybean, 
and walnut oils are similar or higher than that of α-tocopherol (for review see 
[57]). Though some of the studies did control for extreme variances in diet however it 
cannot be discounted that variances in diet between AD patients and controls might 
have affected levels of the tocopherls [58]. A further consideration is that diet  including 
intake of tocopherols [59] has been shown to influence gut microbiota, and gut 
microbiota has in turn been linked with AD [60].  
In conclusion, this meta‐analysis based on case‐control studies demonstrates that 
serum vitamin E concentration is lower in patients with AD and poor cognition than in 
the age-matched controls. This suggests that low‐serum vitamin E levels may be a 
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Figure 1. Study Flow Diagram. 
 
Figure 2. Standardized mean difference (SMD) and 95% confidence interval (CI) of 
serum α-tocopherol levels for AD and age-matched controls. Studies were sub-
grouped dependent on if tocopherol levels were controlled for total cholesterol (TC) 
or not. 
  
Figure 3. SMD and 95% CI of serum α-tocopherol levels for MCI and age-matched 
controls. Studies we sub-grouped dependent on if tocopherol levels were controlled 
for TC or not. 
 
Figure 4. SMD and 95% CI of serum γ-tocopherol levels for AD and age-matched 
controls. 
 
Figure 5. SMD and 95% CI of serum γ-tocopherol levels for MCI and age-matched 
controls. 
 
Figure 6. SMD and 95% CI of serum β-tocopherol levels for AD and age-matched 
controls. 
 




Figure 8. SMD and 95% CI of serum δ-tocopherol levels for AD and age-matched 
controls. 
 
Figure 9. SMD and 95% CI of serum δ-tocopherol levels for MCI and age-matched 
controls. 
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CC, case-control; CS, cross-sectional, blood test to exclude secondary causes of 
dementia (included measurements of vitamin B 12, folic acid and thyroid hormones); 
Dis., disease; Med., medications; CVD, cerebrovascular disease; VD, vascular 
disease; BMI, body mass index; DM, diabetes mellitus; MNA,  Mini Nutritional 
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Table 2. Characteristics of studies focusing on Age-related poor cognitive function 
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